Article

Landmark ctDNA molecular response represents an early predictor of immunotherapy outcomes in lung cancer: A clinical utility study

2026-02-23

Abstract excerpt

<h4>Purpose</h4> Circulating tumor DNA (ctDNA) analyses are informative as an early indicator of immunotherapy response in advanced non-small cell lung cancer (NSCLC); however, the clinical value of ctDNA molecular response requires further validation. <h4>Patients and Methods</h4> As part of a prospective clinical protocol ( NCT05995821 ), we conducted targeted error-correction sequencing of ctDNA (n=328) and...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 091f4383-3e32-5cac-98e8-901b4ad424f7
DOI: 10.64898/2026.02.18.26346415

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Landmark ctDNA molecular response represents an early predictor of immunotherapy outcomes in lung cancer: A clinical utility studyDOI 10.64898/2026.02.18.26346415Read

Dynamic Surveillance of Minimal Residual Disease via a Tumor-Informed Circulating Tumor DNA Assay for Outcome Prediction in Small-Cell Lung Cancer: A Prospective Pilot StudySemantic proximity Read

Molecular response assessment using circulating tumor DNA (ctDNA) in advanced solid tumors.Semantic proximity Read

Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA.Semantic proximity Read

Decoding circulating tumor DNA to identify durable benefit from immunotherapy in lung cancer.Semantic proximity Read

Improving prediction of survival and progression in metastatic non-small cell lung cancer following immunotherapy through machine learning of circulating tumor DNA dynamicsSemantic proximity Read

Brief Report: Methylation-Based ctDNA Serial Monitoring Correlates With Immunotherapy Response in NSCLCSemantic proximity Read

Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC.Semantic proximity Read

Immune and Circulating Tumor DNA Profiling After Radiation Treatment for Oligometastatic Non-Small Cell Lung Cancer: Translational Correlatives from a Mature Randomized Phase II Trial.Semantic proximity Read

The promises and perils of circulating tumor DNA for monitoring immunotherapy response in non-small cell lung cancerSemantic proximity Read

Dynamics of Sequence and Structural Cell-Free DNA Landscapes in Small-Cell Lung CancerSemantic proximity Read

Integrating clinico-pathological features and longitudinal liquid biopsy results to predict clinical benefit from immune checkpoint Inhibitors in advanced Non-Small Cell Lung Cancer patientsSemantic proximity Read

Tumour informed workflow to use ctDNA as a biomarker for risk of recurrence in head and neck cancer patients post-treatmentSemantic proximity Read